# ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

> **NCT07392723** · PHASE2 · RECRUITING · sponsor: **Michal Schnaider Beeri, Ph.D.** · enrollment: 20 (estimated)

## Conditions studied

- Cognitive Dysfunction
- Alzheimer Disease
- Blood-Brain Barrier
- Apolipoprotein E, Deficiency or Defect of
- Brain Aging
- Fatty Acids, Omega-3

## Interventions

- **DRUG:** Alpha-Linolenic Acid (2.6 g/day)
- **DIETARY_SUPPLEMENT:** Placebo Control Group

## Key facts

- **NCT ID:** NCT07392723
- **Lead sponsor:** Michal Schnaider Beeri, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-12
- **Primary completion:** 2027-04
- **Final completion:** 2027-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392723, "ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07392723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*